Applications
Operating excellence in a whole range of medical fields

Psoriasis & Vitiligo

CONTACT US
Name* :
 
Family Name* :
Country* :
select
 
E-mail* :
Message* :
Type the code from the image

I have read and approved your Privacy Policy (View)
accept not accept
 
I agree to receive, from time to time, information on DEKA products, services and events.
accept not accept
Overview
MEL@308 (Monochromatic Excimer Light @ 308nm) is DEKA's innovative monochromatic excimer light source.
The MEL@308nm laser, state-of-the-art in phototherapy for the treatment of psoriasis and vitiligo, utilizes the most effective wavelength, offering numerous advantages over equivalent treatments with other excimer lasers. In fact, with the MEL@308nm laser it is possible to selectively treat lesions, even when extensive, in only a few seconds without involving the healthy skin. The total irradiation is reduced to a minimum, combining the great therapeutic benefits of this wavelength with the safety of limited exposure to ultraviolet rays. A few weeks' treatment eliminates symptoms for several months. Treatment is extremely well tolerated, painless and with hardly any impact on the patient's working and social activities.

Experimentation has demonstrated the efficacy of DEKA's MEL@308nm light sources for the clinical symptoms of psoriasis on elbows, knees, back, soles of the feet, and palms of the hand, generating prolonged remission of the disease and considerably enhancing the patient's quality of life.

Trials on vitiligo have demonstrated cases with an acceptable to excellent degree of re-pigmentation on the face, neck, back, abdomen, and limbs.

What is Psoriasis?

Psoriasis is chronic, relapsing, non-contagious dermatosis with an unpredictable evolution, usually characterised by roundish erythematous-desquamative patches on the elbows, knees, scalp, palms of the hand, soles of the feet, and at times involving the whole body.

It is not contagious, occurs frequently (in 2-3% of the population) and affects both sexes of all ages.

What is Vitiligo?

This is an acquired pigmentation disorder in the form of depigmentated areas lacking in skin melanin. Vitiligo patches often have irregular, well-defined borders without any atrophy or hyperkeratosis.

Vitiligo affects 1-2% of the population worldwide of all ages, races, and sex.

 

How it works

Molecular biology and immunohistochemical (IHC) studies have demonstrated how irradiation of the skin with MEL@308nm causes a precocious reduction of the T-lymphocytes of the infiltrate at both an epidermal and dermal level within 24 to 48 hours, even after only one session.

This suggests that the MEL@308nm light source has a direct effect on the cellular infiltrate, demonstrated by the drastic decrease in the expression of inflammatory cytokines involved in the pathogenetic mechanism of psoriasis (IL-6, IL-8, TGF-α, TNF-α and INF-γ).

After treatment, a rapid increase in the expression of the mediatric proteins of the apoptotic process (p53) is recorded, combined with a reduced expression of the anti-apoptotic proteins (Bcl-2) and the cellular proliferation process (Ki-67).

Even after just one treatment, the thickening of the nuclear chromatin of the epidermal layers is the earliest sign of the beginning of the apoptotic process, and clearly indicates that the route followed by the epidermis and the infiltrate towards healing is that of programmed cell death.